ImmunoPrecise Antibodies Ltd. (IPA): Price and Financial Metrics
IPA Price/Volume Stats
| Current price | $1.28 | 52-week high | $4.22 |
| Prev. close | $1.26 | 52-week low | $0.94 |
| Day low | $1.25 | Volume | 57,800 |
| Day high | $1.33 | Avg. volume | 456,541 |
| 50-day MA | $1.49 | Dividend yield | N/A |
| 200-day MA | $1.70 | Market Cap | 33.68M |
IPA Stock Price Chart Interactive Chart >
ImmunoPrecise Antibodies Ltd. (IPA) Company Bio
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Latest IPA News From Around the Web
Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call TranscriptImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript December 14, 2023 ImmunoPrecise Antibodies Ltd. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.09. Operator: Good morning, ladies and gentlemen. Thank you for joining us today for IPA’s Earnings Call covering the Second Quarter of Fiscal Year 2024. I am Sarah and I have […] |
ImmunoPrecise Antibodies Ltd. (IPA) Q2 2024 Earnings Call TranscriptImmunoPrecise Antibodies Ltd. (IPA) Q2 2024 Earnings Conference Call December 14, 2023 10:30 AM ET Company Participants Jennifer Bath - President and Chief Executive Officer Kristin Taylor - Chief Financial Officer Conference Call Participants Arthur He - H.C. Wainwright Will McHale - Ingalls & Snyder Presentation Operator Good morning, ladies and gentlemen. Thank you for joining us today for IPA’s Earnings Call covering the Second Quarter of Fiscal Year 2024. I am Sarah and I have the privilege of hosting this call. Before we commence, I would like to draw your attention to the fact that our discussion today may include forward-looking state... |
IPA Stock Earnings: ImmunoPrecise Antibodies Beats EPS, Beats Revenue for Q2 2024IPA stock results show that ImmunoPrecise Antibodies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. |
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*VICTORIA, British Columbia, December 14, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year ("FY24"), which ended October 31, 2023. |
IPA Announces Closing of $1.265 Million Public Offering of Common SharesVICTORIA, British Columbia, December 08, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each common share, before the underwriter’s discount and commissions, was $1.00. All of the securities in the |
IPA Price Returns
| 1-mo | -11.11% |
| 3-mo | -44.35% |
| 6-mo | -20.99% |
| 1-year | -52.56% |
| 3-year | -83.11% |
| 5-year | N/A |
| YTD | -25.15% |
| 2023 | -67.18% |
| 2022 | -2.80% |
| 2021 | -64.15% |
| 2020 | 579.08% |
| 2019 | N/A |
Loading social stream, please wait...